Acquisitions, Dividends, and Positive Data - Research Report on Onyx, Johnson & Johnson, Medtronic, Lilly, and Incyte

NEW YORK, August 29, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Johnson & Johnson (NYSE: JNJ), Medtronic, Inc. (NYSE: MDT), Eli Lilly and Company (NYSE: LLY), and Incyte Corporation (NASDAQ: INCY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Onyx Pharmaceuticals, Inc. Research Report

On August 25, 2013, Onyx Pharmaceuticals, Inc. (Onyx) and Amgen Inc. announced that their Boards of Directors have unanimously approved a transaction, under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. Onyx reported that the acquisition is valued at $10.4 billion, or $9.7 billion net of estimated Onyx cash. Robert A. Bradway, Chairman and CEO of Amgen, stated, "Our acquisition of Onyx follows a thorough due diligence process and is fully consistent with our strategy of advancing innovative medicines that address serious unmet medical needs. We expect this acquisition will accelerate growth and enhance value for Amgen shareholders." The Full Research Report on Onyx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/fcf2_ONXX]

--

Johnson & Johnson Research Report

On August 19, 2013, Johnson & Johnson announced the successful acquisition of Aragon Pharmaceuticals, Inc., a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. Peter F. Lebowitz, M.D., Ph.D., Global Therapeutic Area Head of Oncology at Johnson & Johnson, commented, "The acquisition strengthens our prostate cancer pipeline with a second-generation, potentially best-in-class compound." Lebowitz added, "It builds on our existing leadership position with ZYTIGA (abiraterone acetate), and, if approved, we are hopeful ARN-509 will allow us to meet the needs of an even broader range of prostate cancer patients." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/07a8_JNJ]

--

Medtronic, Inc. Research Report

On August 22, 2013, Medtronic, Inc. (Medtronic) announced that its Board of Directors has approved a cash dividend of $0.28 per common share, which is up 7.7% YoY. Medtronic reported that the dividend is payable on October 25, 2013, to shareholders of record at the close of business on October 4, 2013. The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/bc94_MDT]

--

Eli Lilly and Company Research Report

On August 15, 2013, Eli Lilly and Company (Lilly) announced that data published in The Lancet showed that elderly people with type 2 diabetes treated for 24 weeks with dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (TRADJENTA) experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo. The Company added that the overall safety and tolerability profile of linagliptin was similar to placebo. Professor Anthony H. Barnett, MD, FRCP, Heart of England NHS Foundation Trust and University of Birmingham, United Kingdom, said, "Elderly individuals represent approximately 15 percent of people with type 2 diabetes worldwide." Barnett continued, "This study may help inform treatment decisions for improving glycemic control in the elderly." The Company also informed that TRADJENTA is marketed by Lilly and Boehringer Ingelheim Pharmaceuticals, Inc. The Full Research Report on Eli Lilly and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/977d_LLY]

--

Incyte Corporation Research Report

On August 21, 2013, Incyte Corporation (Incyte) announced that it has achieved top-line results for its Phase II, randomized, double-blind, placebo-controlled RECAP trial of ruxolitinib, its oral JAK1 and JAK2 inhibitor, in combination with capecitabine in patients with recurrent or treatment refractory metastatic pancreatic cancer. Paul A. Friedman, M.D., President and CEO of Incyte, stated, "Results of the RECAP trial provide the first evidence that JAK inhibition is active in this disease and suggest a demonstrable survival benefit in a well-defined group of patients with refractory metastatic pancreatic cancer who can be identified without the development of a companion diagnostic test. Coupled with the overall survival benefit observed in the ongoing Phase III trials in myelofibrosis, these results solidify our belief in the therapeutic opportunity that exists for Jakafi, and provide us with an acceleration strategy to advance our JAK1 inhibitor portfolio into additional areas of unmet medical need." The Full Research Report on Incyte Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/076e_INCY]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner